Kevin James Hunt, MD in Hamden, CT - Allergy & Immunology

Kevin James Hunt, MD is a Allergy & Immunology - Allergy physician based in Hamden, Connecticut. Kevin James Hunt is licensed to practice in Connecticut (license number 18057) and his current practice location is 2447 Whitney Ave, Hamden, Connecticut. He can be reached at his office (for appointments etc.) via phone at (203) 288-5558.

NPI number for Kevin James Hunt is 1225106867 and his current mailing address is 2447 Whitney Ave, Hamden, Connecticut. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1225106867.

Contact Information

	Kevin James Hunt, MD
	2447 Whitney Ave, Hamden, CT 06518-3211
	(203) 288-5558
	(203) 288-8651

Physician's Profile

Full Name	Kevin James Hunt
Gender	Male
Speciality	Allergy & Immunology - Allergy
Location	2447 Whitney Ave, Hamden, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1225106867
Provider Enumeration Date: 12/01/2006
Last Update Date: 05/22/2013

Medical Identifiers

Medical identifiers for Kevin James Hunt such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1225106867	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207KA0200X	Allergy & Immunology - Allergy	18057 (Connecticut)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kevin James Hunt is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kevin James Hunt, MD 2447 Whitney Ave, Hamden, CT 06518-3211 Ph: (203) 288-5558	Kevin James Hunt, MD 2447 Whitney Ave, Hamden, CT 06518-3211 Ph: (203) 288-5558

News Archive

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.

Spread of coronavirus extends far beyond Wuhan and other quarantined cities

Infectious disease researchers at The University of Texas at Austin and other institutions in Hong Kong, mainland China and France have concluded there is a high probability that the deadly Wuhan coronavirus spread beyond Wuhan and other quarantined cities before Chinese officials were able to put a quarantine in place.

Americans are divided about health reform proposals overall, but the public, including critics, becomes more supportive when told about key provisions

A new Kaiser Family Foundation poll finds that Americans are divided over congressional health reform proposals, but also that large shares of people, including skeptics, become more supportive after being told about many of the major provisions in the bills.

Kevin James Hunt, MD - Allergy & Immunology in Hamden, CT